(Q44775993)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19945135%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19945135%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19945135%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

4

Hanneke Schuitemaker

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19945135%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Marilie S D Lobbrecht

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19945135%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Ad C van Nuenen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19945135%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

27 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19945135%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19945135%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

397

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19945135%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19945135%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

224-230

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19945135%20AND%20SRC:MED&resulttype=core&format=json

Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Reversion of CTL escape–variant immunodeficiency viruses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

HIV evolution: CTL escape mutation and reversion after transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Characterization of HIV-1 neutralization escape mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Antiviral antibodies are necessary for control of simian immunodeficiency virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Selection of HIV variants with signature genotypic characteristics during heterosexual transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV p24gag

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Isolation and propagation of HIV-1 on peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

The host environment drives HIV-1 fitness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

Rapid and simple method for purification of nucleic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.11.009